- Nachrichtendetail
-
24.04.2024 16:26:17 - dpa-AFX: *IMMUTEP: PHASE IIB TRIAL SHOWS POSITIVE RESULTS IN FIRST-LINE HNSCC TREATMENT WITH EFTILAGIMOD ALPHA
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Merck & Co | A0YD8Q | NYSE | 129,030 | 04.06.24 21:49:11 | +0,610 | +0,47% | 129,020 | 129,040 | 127,150 | 128,420 |
